LY305
LY305 is a transdermally bioavailable selective androgen receptor modulator developed by Eli Lilly for the treatment of osteoporosis in men. Its chemical structure includes N-arylhydroxyalkyl. A phase one trial found promising results.
LY305 is a transdermally bioavailable selective androgen receptor modulator developed by Eli Lilly for the treatment of osteoporosis in men. Its chemical structure includes N-arylhydroxyalkyl. A phase one trial found promising results.